Physician profile
Susan Voss
NPI 1023073145
$628.66
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $133 · 2021: $84.47 · 2022: $102 · 2023: $118 · 2024: $20.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $238.02 | 2019-2023 | Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $109.71 | 2019-2024 | Vaxneuvance, Gardasil 9, Proquad |
| Tris Pharma INC | $91.84 | 2019-2020 | |
| Sanofi Pasteur INC. | $34.36 | 2020-2023 | |
| Sobi, INC | $32.04 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.28 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.69 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.48 | 2023 | Flumist Quadrivalent |
| Ironshore Pharmaceuticals INC. | $16.09 | 2019 | |
| Genentech USA, INC. | $15.37 | 2021 | |
| Abbvie INC. | $12.64 | 2021 | |
| Biofrontera INC. | $4.14 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.